Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,309,500.00 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00. Following the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

William Lewis also recently made the following trade(s):

• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Price Performance

Shares of Insmed stock opened at $69.86 on Monday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company’s 50-day moving average price is $71.62 and its two-hundred day moving average price is $72.48. The stock has a market cap of $12.50 billion, a PE ratio of -12.59 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. Insmed’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.10) EPS. As a group, sell-side analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Bank of America boosted their price objective on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Truist Financial restated a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Institutional Investors Weigh In On Insmed

Several large investors have recently modified their holdings of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Insmed during the third quarter valued at $30,000. GAMMA Investing LLC lifted its stake in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the period. Blue Trust Inc. increased its position in shares of Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. acquired a new stake in shares of Insmed during the third quarter valued at approximately $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.